// App-Quantinova.ai

PO1647 : Results from the Ongoing Phase 2 Open-Label Extension Study of Lumasiran, an Investigational RNAi Therapeutic, in Patients with Primary Hyperoxaluria Type 1 (PH1)

Researchers

Presenter

  • Frishberg Yaacov

Principal Investigators

  • Hulton Sally

  • Cochat Pierre

  • Groothoff Jaap

  • Magen Daniella

  • Harambat Jerome

  • Schalk Gesa

  • van't Hoff William

  • Lesueur Dayna

  • McGregor Tracy

  • Deschnes Georges

Medical Centers

  • Shaare Zedek Medical Center, Jerusalem, Israel

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • Centre for Rare Renal Diseases & Inserm Pediatric Clinical Investigation Centre – Hospices Civils de Lyon and Université de Lyon Lyon France

  • University of Amsterdam, Amsterdam, Netherlands

  • Rambam Health Care Campus, Haifa, Israel

  • Bordeaux University Hospital, Bordeaux, Aquitaine, France

  • University Clinic Bonn, Bonn, Nordrhein-Westfalen, Germany

  • Great Ormond Street Hospital for Children, London, England, United Kingdom

  • Alnylam Pharmaceuticals Cambridge Massachusetts United States

  • Hosp Robert Debre, Paris, France

Locations

  • Israel

  • United Kingdom

  • France

  • Netherlands

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

Disease

  • Primary hyperoxaluria type 1

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved